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Abstract: Lung cancer remains the leading cause of cancer-related deaths in southern Africa. Early trials 
of chest radiograph-based screening in males at high risk for lung cancer found no mortality benefit of 
a radiograph alone, or a radiograph plus sputum cytology screening strategy. Large prospective studies, 
including the National Lung Screening Trial, have shown an all-cause mortality benefit when low-
dose computed tomography (LDCT) was used as a screening modality in patients that are at high risk of 
developing lung cancer. The South African Thoracic Society, based on these findings, and those from several 
international guidelines, recommend that annual LDCT should be offered to patients between 55–74 years 
of age who are current or former smokers (having quit within the preceding 15 years), with at least a 30-pack 
year smoking history and with no history of lung cancer. Patients should be in general good health, fit for 
surgery, and willing to undergo further investigations if deemed necessary. Given the high local prevalence 
of tuberculosis (TB) infection and post-TB lung disease, which can radiographically mimic lung cancer, a 
conservative threshold (nodule size ≥6 mm) should be used to determine whether the baseline LDCT screen 
is positive (thus nodules <6 mm require no action until the next annual screen). If a non-calcified, solid or 
partly solid nodule is ≥6 mm, but <10 mm with no malignant features (e.g., distinct spiculated margins), the 
LDCT should be repeated in 6 months. If a solid nodule or the largest component of a non-solid nodule  
is ≥10 or ≥6 mm and enlarging or with additional malignant features present, definitive action to exclude 
lung cancer is warranted. Patients should be screened annually until 15 years have elapsed from date of 
smoking cessation, they turn 80, become unfit for a curative operation or significant changes are observed.
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Introduction
Lung cancer is the leading cause of cancer-related deaths 
in the world among men and woman (1). Worldwide more 
than 2 million new cases and almost 1.8 million deaths 
from lung cancer occurred in 2018 (1). In South Africa, 
lung cancer similarly ranks as the number 1 cause of cancer 
deaths (2) with the age standardised incidence rate (ASR) 
3.95/100,000 in females and 10.12/100,000 in males (3).
The most important risk factor for lung cancer remains 
tobacco smoking. It is estimated that 33.4% of males and 
8.3% of females above the age of 15 are consumers of 
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tobacco in South Africa (4). Other factors such as a family 
history, poor diet, chronic obstructive pulmonary disease 
(COPD), ionising radiation, human immunodeficiency virus 
(HIV) infection, occupational exposures and air pollution 
may also predispose to lung cancer (5). 
The prognosis for non-small cell lung cancer is directly 
related to the stage at the time of diagnosis. Based on the 
current TNM classification, five-year survival using clinical 
staging ranges from 92% (stage IA) to zero (stage IVB) (6). 
In the USA, only 25% of patients with lung cancer are 
potentially amenable to cure on presentation (7). In South 
Africa, the outlook is even bleaker, as <10% of patients have 
potentially curable disease at presentation (8). There is even 
evidence to suggest that having access to private medical 
care does not necessarily influence the tendency to present 
too late (9).
At face value, screening for lung cancer seems highly 
appropriate, given that smoking is the major identified risk 
factor (which allows the targeting of high-risk individuals) 
along with the high prevalence of lung cancer, the high 
associated morbidity and mortality, the protracted 
preclinical phase, and the clear evidence that therapy is 
more effective the earlier the diagnosis is made (10). For 
lethal diseases such as lung cancer, disease-specific outcomes 
and overall mortality are the most important outcomes 
when assessing the value of screening (10). In addition 
to the possibility of mortality reduction due to earlier 
disease detection, evidence suggests that participation in a 
randomised controlled trial (RCT) with low-dose computed 
tomography (LDCT) scan has a positive impact on smoking 
cessation (11). Finally, there may be other potential benefits 
including the detection of coronary artery disease (through 
coronary artery calcification scores) and identification of 
those with a higher risk of a cardiovascular event (12). 
Lung cancer screening, on the other hand, may have 
certain disadvantages, particularly in resource-constrained 
settings (13). Diagnostic interventions come at a financial 
burden, some morbidity, and sometimes even mortality (13). 
“Overdiagnosis” bias is also a well-known phenomenon 
and early diagnosis may also not improve survival in those 
with significant comorbidities (14). Moreover, radiation 
exposure from LDCT may over time result in new lung and 
other cancers developing (15). That said, there is supporting 
evidence to suggest that the benefits outweigh the risks in that 
one lung cancer death may be avoided per 320 scanned (16). 
To put this in perspective, mammography saves one life per 
1,339 patients scanned (16). 
Southern Africa is faced with the “colliding epidemics” 
of smoking, HIV and TB, and despite robust international 
evidence to support lung cancer screening in appropriate 
individuals, no local data exist (17). It is within this context 
and background that the South African Thoracic Society 
(SATS) set out to propose local criteria for appropriate lung 
cancer screening. 
Chest radiograph and sputum cytology
Lung cancer screening with chest radiography and/
or sputum cytology has been evaluated in several large 
prospective studies dating as far back as the 1960s, and 
no single trial has shown a mortality benefit (18). The 
Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer 
screening trial was the largest randomised trial (n=154,942 
participants) performed and it demonstrated that annual 
screening with a chest radiograph did not reduce lung 
cancer mortality (19). 
Low-dose chest computed tomography 
General technical aspects and safety 
Modern multidetector LDCT imaging is designed to 
minimise radiation dose while still achieving high quality 
diagnostic images. Today’s modern multidetector CT 
scans obtain adequate resolution while delivering a median 
effective dose of 1.0 mSv for males and 1.4 mSv for females, 
compared to 7 mSv for a standard diagnostic chest CT and 
0.1 mSv for a chest radiograph (20). As a further reference, 
the annual average of the natural background radiation in 
the USA is 3 mSv, and is even higher in some parts of South 
Africa, e.g., Paarl (20,21). 
LDCT are performed without contrast during a single 
maximal inspiratory breath-hold with a scanning time of less 
than 25 seconds (22). High-resolution images (1.0–2.5 mm 
interval) are reconstructed by means of a soft tissue or thin-
section algorithm (20). 
While mSv is an appropriate measurement for a 
population, CT dose Index (CTDI) volume is more 
appropriate when considering radiation exposure in an 
individual. The American college of Radiologists (ACR) 
guideline recommends a CTDI volume of <3 mGy for 
an average sized patient (23). This would be adjusted 
downwards for a smaller patient and upwards for a larger 
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patient (as appropriate) (23). 
General interpretation and reporting
Appropriate window settings should be used to visualise 
all anatomical structures in the examination. Lung nodules 
should be described with respect to location, size, margins, 
density (solid, ground glass or part solid) and presence of 
calcification and/or fat (24). Furthermore, comparison 
with previous imaging, if available, is paramount in order 
to assess for interval change of nodules, and to evaluate if 
there are new nodules. Computerized decision support tools 
are useful adjuncts for nodule detection and volumetric 
assessment, and should be used when available (25,26). 
In order to standardize CT reporting and management 
recommendations, to decrease ambiguity in interpretation, 
and to facilitate monitoring of outcomes, standard guidelines 
should be followed. The Lung-RADS™ classification 
system, created by the ACR provides such a guideline 
and SATS recommends the use of the current revised 
The Lung-RADS™ version 1.1 as the standard reporting 
guideline. The use of automated Lung-RADS™, where 
available, would not only assist the reporting radiologist 
to become more accurate and efficient in nodule detection 
and categorisation (25-27), but also access the benefits of 
the standardised interpretation, reporting and management 
recommendations provided by Lung-RADS™ itself.
Evidence
The National Lung Screening Trial (NLST) was a 
randomised trial comparing annual screening by LDCT 
with a chest radiograph at 33 centres in the USA for three 
years in more than 50,000 high-risk individuals (at least 
30 pack years of smoking and aged 55–74 years) (Table 1) (16). 
The participants were randomly assigned to undergo annual 
screening with both modality for 3 years. Nodules or other 
suspicious findings were classified as positive results. In 
total, 27.3% of patients in the low-dose CT group and 
9.2% in the radiography group had a positive screening 
result. Lung cancer was diagnosed in 1.1% in the low-
dose CT group versus 0.7% in the radiography group. For 
those undergoing at least one screen, the number needed 
to screen with LDCT to prevent one lung cancer death was 
320 and the NLST was terminated early after an interim 
analysis found a statistically significant benefit for LDCT 
scanning (16). At a median follow-up of 6.5 years, there 
were 645 cases of lung cancer per 100,000 person-years in 
the LDCT group, and 572 cases per 100,000 person-years 
in the chest radiograph group, resulting in an incidence rate 
ratio of 1.13 (95% CI: 1.03–1.23). Lung cancers detected 
by screening were mostly stage I or II (70% CT detected vs. 
57% radiograph detected). Per 100,000 person years, there 
were 247 lung cancer deaths in the CT group and 309 in 
the radiograph group, yielding a relative mortality reduction 
of 20% (95% CI: 3.8–26.7) and an absolute reduction 
of 62 lung cancer deaths per 100,000 person years. Of 
significance was the 6.7% (95% CI: 1.2–13.6) relative 
reduction in all-cause mortality in the LDCT group and an 
absolute reduction of 74 deaths per 100,000 person-years. 
Fewer stage IV cancers were observed in the LDCT group 
than the chest radiograph group with the second and third 
screening rounds, suggesting that diagnosis of earlier-stage 
cancers reduced the occurrence of later-stage lung cancers. 
The Nederlands-Leuvens Longkanker Screenings 
Onderzoek (NELSON) trial was a RCT comparing LDCT 
Table 1 Positive result definition of various screening (28) 
Program Positive Indeterminate
NLST Non-calcified nodules ≥4 mm N/A
I-ELCAP At least one solid or partly solid non-calcified pulmonary nodule ≥5 mm; 
or at least one nonsolid non-calcified pulmonary nodule ≥8 mm
N/A
NELSON A solid component of any non-calcified nodule ≥500 mm3 (>9.8 mm in 
diameter)
Volume of the largest solid nodule or of the solid 
component of a partially solid nodule: 50–500 mm3 
(4.6–9.8 mm in diameter); or a nonsolid nodule ≥8 mm
ITALUNG At least one non-calcified solid nodules ≥5 mm or a non-solid  
nodule ≥10 mm or the presence of a part-solid nodule
N/A 
NLST, National Lung Screening Trial; I-ELCAP, International Early Lung Cancer Action Project; NELSON, Nederlands-Leuvens Longkanker 
Screenings Onderzoek; ITALUNG, Italian Lung; N/A, not applicable.
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screening at increasing intervals (1, 2, and 2.5 years) with no 
screening in almost 16,000 current or former smokers in the 
Netherlands and Belgium (Table 1) (11,29-31). Unlike other 
screening studies, five-year lung cancer survivors, a group at 
very high risk of developing a new lung cancer, were eligible 
for enrolment. In a prespecified analysis, after a median of 
8.16 years of follow-up, lung cancer was detected in 3% 
of the screened participants, with two thirds being stage 
1 disease (31).
In the International Early Lung Cancer Action Project 
(I-ELCAP), screening resulted in a diagnosis of lung cancer 
in 484 participants. Of these, 412 (85%) had clinical stage 
I lung cancer, and the estimated 10-year survival rate was 
88% in this subgroup (95% CI, 84–91). Among the 302 
participants with clinical stage I cancer who underwent 
surgical resection within 1 month of diagnosis, the survival 
rate was 92% (95% CI, 88–95). The eight participants with 
clinical stage I cancer who did not receive treatment died 
within 5 years of the diagnosis.
A retrospective interpretation of data from the I-ELCAP 
study cohort and NLST suggested that setting a more 
conservative threshold of ≥6 mm would decrease the false-
positive rate (resulting in fewer unnecessary procedures or 
follow-up studies) with minimal impact on the detection 
of cancers (32,33). As such, compared with the NLST, the 
Lung-RADS criteria have a more conservative threshold for 
a positive baseline screen (≥6 mm) and require pre-existing 
nodules to demonstrate growth (27,34). 
Lung cancer screening in Southern Africa
Patient selection and practical considerations 
Screening should only be performed in centres with 
requisite expertise in LDCT and lung cancer management, 
and only when the clinician and patient are committed 
to pursuing further investigations, including imaging and 
possible biopsy (and where appropriate, surgery or other 
modalities of cancer therapy) (35). Patients at risk need to 
be identified, and appropriately counselled. Lung cancer 
screening in southern Africa, as is the case globally, remains 
a multidisciplinary team effort with commitment from the 
funders, the community, the clinicians, the radiologists and 
ultimately the patient. 
For individuals who opt to be screened after appropriate 
counselling, SATS recommends that annual screening with 
LDCT scanning only be available for those who meet all of 
the following criteria:
 Age 55–74 years;
 Current or former smokers (having quit within 
the preceding 15 years) with at least a 30 pack year 
history;
 No history of lung cancer;
 Are in general good health and fit for surgery. 
Patients should be screened annually until 15 years 
have elapsed from date of smoking cessation, they turn 80, 
become unfit for a curative operation or significant changes 
(see below) are observed.
Suggested LDCT protocols within a TB-endemic setting
Protocols will be specific to each scanner as variability exists 
among scanners. There are, however, minimum equipment 
specifications required to achieve the recommended 
radiation targets; these include (23): 
 Gantry rotation times of ≤0.5 seconds;
 Slice thickness of ≤2.5 mm (preferably ≤1.0 mm);
 Detector rows of ≥16;
 The CT scanner and/or the viewing platform 
should be capable of generating maximum intensity 
projection (MIP) and multiplanar reformation 
(MPR) images.
SATS recommends that the examination guidelines set 
by the American College of Radiology should be followed, 
including that (23): 
 LDCT should be performed without contrast 
during a single maximal inspiratory breath-hold 
with a scanning time of less than 25 seconds (22); 
 The field of view must include axial images from 
the lung apices to the costophrenic sulci; 
 The examination should be acquired at ≤2.5 mm 
slice thickness (soft tissue may be viewed at 
2.5 mm);
 Lung algorithms should be reconstructed at ≤1.0 mm 
slice thickness to allow for better characterization 
of small lung nodules;
 Use of MIP reconstruction to increase lung nodule 
detection and MPR to further characterize nodules, 
particularly along the pleural/fissural surfaces.
There is a high burden of TB in southern Africa with 
South Africa, according to the 2018 Global Report, 
having the highest incidence amongst the 30 high burden 
countries (36). Granulomas from previous TB infection 
(which may calcify) and those due to active disease 
frequently manifest as solitary or multiple nodules in any 
part of the lung (though the upper zones predominate). 
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Solitary pulmonary nodules may also be due to non-
tuberculous mycobacteria and should be considered even 
in TB endemic regions particularly where the incidence 
of HIV co-infection is high (37). The natural history of 
SPN due to TB is unclear but disease progression may be 
slow over the short term (less than 4 years) (38). Given 
these considerations, and the lack of local data on the 
utility of LDCT in our population, SATS recommends 
a conservative threshold for a nodule to be considered 
positive at baseline (≥6 mm), and that pre-existing nodules 
should demonstrate growth (27). This is in line with 
the revised Lung-RADS™ 1.1 guidelines, which would 
categorize solid and partly solid nodules <6 mm as benign 
or to have an appearance consistent with a negative scan (25). 
If a non-calcified solid or partly solid nodule is ≥6 mm, but 
<10 mm with no malignant features (e.g., clearly spiculated 
margins), the LDCT should be repeated in 6 months. If a 
solid nodule or the largest solid component of a non-solid 
nodule is ≥10 or ≥6 mm and it is enlarging or has additional 
malignant features, definitive action to exclude lung cancer 
is warranted (Figure 1). Appropriate investigations in this 
setting would include a standard contrasted CT scan of 
the chest and upper abdomen, followed by tissue sampling 
(either percutaneously, endoscopically, or surgically). 
Non-surgical tissue sampling may have an appreciable 
diagnostic yield for TB and could therefore avoid futile 
surgical intervention (39). A positron emission tomography-
computed tomography (PET/CT) scan may be used to 
guide further management, but will be of limited value 
in distinguishing between TB or malignancy, unless the 
standardized uptake value (SUV) value is >5, in which case 
the PET scan has a high specificity for cancer (40).
Surgical intervention and potential downsides
Lung cancer screening has the potential to save lives. 
The downside, however, is the potential for unnecessary 
surgery and the resultant morbidity that may ensue (13). 
This stresses the importance of a dedicated team with 
management decisions made by consensus. Stage I 
lung cancer is amenable to minimally invasive thoracic 
surgery (6). Video-assisted thoracic surgery (VATS) which 
started in the early 90s and was initially utilized as a 
diagnostic procedure is now used to perform lobectomies, 
segmentectomies, removal of mediastinal masses and even for 
lymph node dissection. VATS procedures, especially for stage 
I lung cancer have become the modern standard, avoiding 
the necessity for an open thoracotomy which has far more 
potential for significant morbidity and mortality (41). 
Concomitant program recommendations
All hospital patients whether or not they are being 
investigated for lung cancer should be encouraged to stop 
smoking and referred to a smoking cessation program if 
one is available, as prevention is likely to have a far greater 
High-risk individual willing to undergo screening and further investigations 
Annual LDCT
Until 80 years old, becomes unfit for surgery  





Non-calcified solid or partly solid 
nodule is ≥6 mm, but <10 mm with 
no malignant features
Solid nodule or the 
largest solid component 
of a non-solid nodule 
is ≥10 or ≥6 mm and 
enlarging or with 
additional malignant 
features present
No growth LDCT in six months
Growth
Positive nodule
Figure 1 A suggested algorithm for lung cancer screening in southern Africa. High-risk individuals are those 55–74 years who are current 
or former smoker (having quit within the preceding 15 years) with at least a 30-pack year history, have no history of lung cancer and are in 
general good health and fit for surgery. LDCT, low-dose computed tomography.
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impact on lung cancer mortality than does screening (4). 
Stakeholder education is important, as is access to a 
multidisciplinary team to educate, advise and potentially 
manage lung cancer or other incidental findings. 
Conclusions 
Lung cancer is the leading cause of cancer-related death 
in South Africa. Early trials of chest radiograph-based 
screening in males at high risk for lung cancer found no 
mortality benefit for a radiograph alone or a strategy 
utilizing both a radiograph and sputum cytology. Large 
prospective studies, including the NLST, have shown 
an all-cause mortality benefit when LDCT was used as 
a screening modality in patients that are at high risk of 
developing lung cancer. The SATS, based on these findings 
and numerous international guidelines (42), suggest that 
annual LDCT should be offered to patients 55–74 years 
who are current or former smokers (having quit within 
the preceding 15 years) with at least a 30 pack year history 
and with no history of lung cancer. Patients should be 
in general good health, fit for surgery and willing to 
undergo further investigations if deemed necessary. Given 
the high local prevalence of tuberculous lung disease, 
we recommend a conservative threshold of ≥6 mm for a 
positive baseline screen. If a non-calcified solid or partly 
solid nodule is ≥6 mm, but <10 mm with no malignant 
features (e.g., with a clearly spiculated margin), the 
LDCT should be repeated in 6 months. If a solid nodule 
or the largest solid component of a non-solid nodule 
is ≥10 or ≥6 mm and enlarging or has additional malignant 
features present, definitive action to exclude lung cancer 
is warranted. Patients without these features should be 
screened annually until 15 years have elapsed from the 
date of smoking cessation, they turn 80, become unfit for 
surgery or significant changes are observed.
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